Wells Fargo downgraded Glaukos (GKOS) to Equal Weight from Overweight with a price target of $86, down from $160. The growth runway for iDose is priced into the shares while the base business offers no upside, the analyst tells investors in a research note. Wells says its sum-of-the-parts analysis indicates Glaukos’ iDose growth runway is priced in at current share levels. Meanwhile, the company’s base business is expected to grow flat year-over-year in fiscal 2025, contends the firm.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Glaukos downgraded to Equal Weight from Overweight at Wells Fargo
- Positive Buy Rating for Glaukos Amid Strong iDose Performance and Awaited FDA Decision
- Glaukos’s Promising Outlook: Buy Rating Amid Strong Sales and Strategic Growth Opportunities
- Glaukos Corp. Reports Strong Q1 2025 Growth
- Closing Bell Movers: Microsoft and Meta rally after earnings